Humana Inc.

(New York Stock Exchange)
Back to all articles
Very Bullish +85

Humana Surges as Star Ratings Reset Beats Fears | AVALW

Analyst upgrade Company update Earnings report AI-generated analysis

πŸ“ˆ Humana shares jumped 16 percent after hours and closed up 11.47 percent following the release of better-than-feared 2027 Medicare Advantage Star ratings on October 9, 2026.

πŸ† Barclays upgraded Humana to Overweight with a $515 price target, while Cantor Fitzgerald raised its rating and set a $460 target, citing improved margins and strategic positioning.

πŸ’° The company reported quarterly revenue of $40.9 billion and net income of $694 million, demonstrating strong profitability in the managed care sector.

πŸ›‘οΈ Humana maintains a robust balance sheet with a low debt-to-equity ratio of 0.12 and generated $1.83 billion in free cash flow during the latest quarter.

πŸš€ The insurer is expanding Chronic Condition Special Needs coverage across approximately 2,600 counties to target specific patient segments and manage costs effectively.

πŸ“‰ While Humana rallied, rivals such as CVS and Alignment Healthcare saw their stocks sell off, highlighting Humana's relative strength in the sector.

πŸ’‘ The positive ratings reset removed a significant overhang, providing clarity and confidence in Humana's ability to maintain its market position against regulatory uncertainty.

Bullish Signals
  • Humana stock surged 16 percent after hours and closed up 11.47 percent following the release of better-than-expected 2027 Medicare Advantage Star ratings, signaling a major positive sentiment shift.
  • Barclays upgraded its rating on Humana to Overweight and raised its price target to $515, betting that key Medicare Advantage contracts will regain bonus status.
  • Cantor Fitzgerald boosted its rating to Overweight with a $460 price target, highlighting stronger Medicare Advantage margins and future Star ratings as key catalysts for growth.
  • The company generated substantial quarterly revenue of $40.9 billion and net income of $694 million, proving the core business remains highly profitable despite tight industry margins.
  • Humana maintains a robust balance sheet with a conservative debt-to-equity ratio of just 0.12, allowing it to handle economic shocks better than many competitors.
  • The insurer produced $1.97 billion in operating cash flow and $1.83 billion in free cash flow, providing significant liquidity to support sustained uptrends and strategic investments.
  • Humana is strategically expanding Chronic Condition Special Needs coverage across approximately 2,600 counties to attract new enrollees while retaining existing ones through value-based care.
  • The company's low price-to-sales ratio of 0.33 suggests the stock looks relatively cheap given its massive revenue stream and growth potential.
Full Analysis
Humana stock surged approximately 16 percent after hours and closed up 11.47 percent following the release of better-than-expected 2027 Medicare Advantage Star ratings by the Centers for Medicare and Medicaid Services on October 9, 2026. The positive surprise in the ratings removed a significant overhang that had weighed on the company's valuation, separating Humana from managed care peers whose stocks declined during the same event. This market reaction signaled a renewed shift in sentiment regarding Humana's operational strength and its ability to maintain a dominant market position within the sector. Major institutional investors responded quickly to the news with bullish actions, as Barclays upgraded its rating on Humana to Overweight and raised its price target to $515. Cantor Fitzgerald followed suit, boosting its rating to Overweight with a higher price target of $460, citing confidence in stronger Medicare Advantage margins and future Star ratings. Analysts collectively viewed the ratings reset as a catalyst that provided clarity on Humana's strategic positioning, validating its competitive advantage against rivals like CVS and Alignment Healthcare. Fundamentally, Humana reported robust financial performance with quarterly revenue of $40.9 billion and net income of $694 million, translating to diluted earnings per share of $5.73. The company maintains a highly conservative balance sheet with a debt-to-equity ratio of just 0.12, generating approximately $1.97 billion in operating cash flow and $1.83 billion in free cash flow for the latest quarter. These strong fundamentals support its strategy of expanding Chronic Condition Special Needs coverage across roughly 2,600 counties while leveraging low premium plans with rich benefits to attract new enrollees.